Trial Profile
TREATMENT WITH CMV PP65-SPECIFIC T CELLS GENERATED BY USE OF A CMV PP65 PROTEIN-SPANNING PEPTIDE POOL IN PATIENTS WITH CMV REACTIVATION OR CMV DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jun 2012
Price :
$35
*
At a glance
- Drugs Cytomegalovirus vaccine vCP260 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions
- 24 Dec 2011 New trial record